New Class of Cancer Vaccine Based on an Off-The-Shelf Antigen Presenting Cell line (PDC*line)

Time: 9:30 am
day: Day Two


  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumour antigen, including neoantigens, specific cytotoxic T cells than conventional vaccines and improves the response to checkpoint inhibitors
  • The technology can be applied for any cancer